Wai Yuen Tong

2016年，公司投資近六億港元在香港元朗工業村興建及運作符合良好生產質量管理規範「GMP」及依照全球公認嚴格的製藥規範「國際醫藥品稽查協約組織」(「PIC/S」)標準的廠房。旗下產品質量嚴格監控，重視產品功能性、安全性和方便性，將博大精深的保健中藥產品推廣至世界各地。 2001年，位元堂藥廠有限公司獲宏安集團注資收購。2002年8月，獲正式注入「位元堂藥業控股有限公司」。2003年，宏安集團將生產珮夫人止咳露的盧森堡大藥廠注入「位元堂藥業控股有限公司」，讓兩家中西藥企業發揮協同效益。位元堂藥業控股有限公司於香港聯交所上市（股份代號：897），透過位元堂藥廠有限公司及盧森堡大藥廠有限公司，分別持有「位元堂」、「珮夫人」及「珮氏」家傳戶曉的中、西醫藥保健品牌，發揮協同效益。

Basic Information

Category: public company
Website: http://www.wyth.net/

Documented Facts

Email: pr@waiyuentong.com (No linked source recorded for this statement.)

Evidence and Sources

Wai Yuen Tong — Official Site (official)

Citation Guidance

Explore public company profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Wai Yuen Tong.

Canonical profile: https://brandsource.ai/brands/wai-yuen-tong
Machine-readable JSON-LD: https://brandsource.ai/api/brands/wai-yuen-tong/json-ld
Citation profile API: https://brandsource.ai/api/brands/wai-yuen-tong/citation-profile
Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
Data status: Enriched
Profile completeness: Structured profile (59/100)
Indexing directive: index, follow, max-image-preview:large
Recorded profile date: 2026-04-21

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

Wai Yuen Tong is listed in public company on BrandSource.AI.

Available profile information

Official website is captured for entity disambiguation.
1 official source linked for verification.
1 structured fact available for extraction.

Known data gaps

Needs a specific, non-thin summary

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.